%0 Journal Article
%T Combining CDP
%A Crystal M Blais
%A Derek Fisher
%A Dhrasti Shah
%A Dylan Smith
%A Joelle Choueiry
%A Vadim Illivitsky
%A Verner Knott
%J Journal of Psychopharmacology
%@ 1461-7285
%D 2019
%R 10.1177/0269881119836217
%X Schizophrenia (SCZ) patients and relatives have deficits in early cortical sensory gating (SG) typically measured by suppression of electroencephalography-derived P50 event-related potentials (ERPs) in a conditioning-testing (S1¨CS2) paradigm. Associated with alpha 7 nicotinic acetylcholine receptor (¦Á7 nAChR) dysfunction and shown to be improved with nicotine and ¦Á7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment. This pilot study in healthy humans assessed the SG effects of an ¦Á7 nAChR strategy combining CDP-choline with galantamine, a positive allosteric modulator (PAM) of nAChRs, aimed at increasing and prolonging nicotinic receptor activity. The combined effect of CDP-choline (500£¿mg) and galantamine (16£¿mg) on speech P50 gating indices rP50 (S2/S1) and dP50 (S1¨CS2) was examined in 30 healthy participants stratified into low and high baseline P50 suppressors in a randomized, double-blind, placebo-controlled and counterbalanced design. In low suppressors, CDP-choline/galantamine (vs. placebo) improved rP50 and dP50 gating, and reduced S2P50 amplitudes. No P50 gating effects were observed in high suppressors; however, CDP-choline/galantamine (vs. placebo) increased their S2P50 amplitudes. Findings from this pilot study with CDP-choline/galantamine in a healthy, SCZ-like surrogate deficient gating sample are consistent with the association of ¦Á7 nAChR mechanisms in SG impairment in SCZ and support further research trials with CDP-choline and galantamine targeting sensory processes
%K ¦Á7 nAChR
%K CDP-choline
%K ERP
%K galantamine
%K P50
%K PAM
%K P50 suppression
%K schizophrenia
%K sensory gating
%U https://journals.sagepub.com/doi/full/10.1177/0269881119836217